Navigation Links
Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
Date:1/3/2011

chool of Medicine.  "Novel regenerative therapies, such as JVS-100, have the potential to restore blood flow and improve outcomes for these patients."

There are approximately 3 million U.S. citizens with critical limb ischemia.  The hospital treatment costs for these patients exceed $10 billion with average in-patient charges surpassing those for stroke or heart attack.  Within a year of CLI diagnosis, up to 50% of patients will undergo an amputation and 25% will die.

The Juventas therapeutic platform is based on discoveries made nearly a decade ago by Marc Penn, M.D., Ph.D., Director of the Bakken Heart-Brain Institute at the Cleveland Clinic and Juventas' Chief Medical Officer.  Dr. Penn demonstrated that SDF-1 is a strong chemo-attractant for hematopoietic stem cells (HSCs), with the potential to promote cardiac repair when delivered to the heart hours to months following a heart attack.  These findings were published in 2003 in The Lancet and have now been validated by several independent laboratories.  The SDF-1 repair pathway is conserved in most end organ systems, including the heart, peripheral vasculature, kidney, skin, liver and eye.

"Our work on SDF-1 originates from the hypothesis that we all have a natural stem cell based repair process that attempts to repair organs following injury," states Dr. Penn.  "We believed that if we could identify the molecular factors that activate this pathway, they could be delivered at a time post-injury to promote tissue preservation.  SDF-1 has proven to be a key player in driving repair and we are excited to see our findings translating to the clinic with the potential to help patients".

About Juventas Therapeutics

Juventas Therapeutics, headquartered in Cleveland, OH, is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007
'/>"/>

SOURCE Juventas Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Zenobia Therapeutics, Inc. Enters Into a Research Collaboration With Lundbeck for the Parkinsons Disease Target LRRK2
2. Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy
3. Talecris Biotherapeutics Announces Jury Verdict in Contract Dispute
4. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
5. Reportlinker Adds Global Bladder Cancer Therapeutics Industry
6. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
7. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
8. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
10. NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
(Date:12/22/2014)... 2014 Fertility Associates of Memphis has ... USA , a network of more than 20 contributing ... patients have fast access to a national pool of ... . Fertility Associates of Memphis is the only fertility ... option. , Dr. William Kutteh , director of ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... , , BETHESDA, Md., July ... and NWBS) today announces that it will seek shareholder approval for ... AIM market ("AIM") (the "De-listing"). The Company plans to continue its ... Board Market ("U.S. listing"), and plans to file an S1 registration ...
... , SAN DIEGO, July 23 Anadys Pharmaceuticals, Inc. ... quarter 2009 financial results on Thursday, July 30, 2009, after the U.S. ... hold a conference call and webcast on Thursday, July 30, 2009 at ... results and highlights and to provide an update on its development programs. ...
... , SUNNYVALE, Calif., July 23 ... for the treatment of chronic total occlusions (CTOs), today announced the ... Chris previously held the position of Executive VP, Sales and Marketing ... Devices including the last 2 years at FlowCardia. , ...
Cached Biology Technology:Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S. 2Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S. 3Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results 2FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer 2
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... release is available in French . ... action to better control the sale of chemicals that ... Lunn, Minister of Natural Resources, and the Honourable Stockwell ... regulations for these chemicals, known as explosives precursors, will ...
... American,Association of Airport Executives President Chip ... Traveler (RT) program with the opening of,RT ... Reagan,Washington National Airport., "The expansion of ... in,the nation,s capital will further highlight the ...
... — Robots are fluent in their native language of 1 ... imprecise nature of human language. While scientists are making slow, ... responds to speech, gestures and body language, a more straightforward ... homes sooner. A team of researchers led by Charlie ...
Cached Biology News:New regulations tighten controls on restricted chemicals 2AAAE Applauds Expansion of Registered Traveler Program to Nation's Capital 2AAAE Applauds Expansion of Registered Traveler Program to Nation's Capital 3Robot fetches objects with just a point and a click 2Robot fetches objects with just a point and a click 3Robot fetches objects with just a point and a click 4
...
Request Info...
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Biology Products: